Promising drug cocktail may halt smoldering myeloma before it starts
NCT ID NCT01572480
First seen Mar 20, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This study tested whether a combination of three drugs (carfilzomib, lenalidomide, and dexamethasone) can safely stop smoldering multiple myeloma from turning into active cancer. Fifty-five adults with high-risk smoldering myeloma received eight cycles of the three drugs, followed by up to 12 more cycles of lenalidomide alone. The goal was to see if the treatment could clear all signs of cancer in the bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.